country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-173639

Copy Link Print Information

AZD0516

Customer Review

Based on 1 Customer Validation

AZD0516 is an antibody-drug conjugate (ADC) targeting STEAP2. It is formed by conjugating an anti-STEAP2 monoclonal antibody (mAb) via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) and the topoisomerase 1 inhibitor Exatecan (HY-13631). AZD0516 is applicable to the research of metastatic castration-resistant prostate cancer.

For research use only. We do not sell to patients.

Purity: 99.15%
Molecular Weight:162163 (average)

Storage:

-80°C, protect from light

AZD0516 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]

Topoisomerase I

All Topoisomerase Isoforms :

In Vitro

AZD0516 potently inhibits prostate cancer cell viability with low nanomolar IC₅₀ values, inducing DNA damage and apoptotic cell death^[1].
AZD0516 mediates bystander cell killing of STEAP2-negative cells in co-culture with STEAP2-positive cells via intracellular release of its Exatecan (HY-13631) payload^[1].
The anti-STEAP2 monoclonal antibody component of AZD0516 exhibits specific binding, rapid internalization, and efficient lysosomal trafficking in prostate cancer cells^[1].
The anti-STEAP2 monoclonal antibody component of AZD0516 binds specifically to human, cynomolgus monkey, mouse, and rat STEAP2, with no cross-reactivity to other STEAP family members^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Liquid
Molecular Weight 162163 (average)
Color Colorless to light yellow
SMILES

[AZD0516]
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Monlish D, et al. Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody‑drug conjugate (ADC) for the treatment of prostate cancer. Cancer Research. 2025 Apr 15;85(8_Supplement_1):1158.

[2]. Ma Z, et al. Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Journal of medicinal chemistry. 2023 Aug 24;66(16):10991-11026. [Content Brief]

[3]. Dunne VL, et al. Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. Cancers. 2024 Apr 15;16(8):1510.

[4]. Burrell PE. GRP94 is a novel ATM interactor and putative substrate which regulates oncogenic receptor expression and microglial activation [dissertation]. Durham (NC): Duke University; 2025 Sep 12.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

AZD0516

Anti-STEAP2 Antibody

Exatecan

All Topoisomerase Isoforms